Advocates on Steps of Congress 2013
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #658 | May 6, 2016  

What's Behind the Heartbreaking Risk of Anti-Inflammatory Drugs

thinkstockphotos-140279061-397x263.jpgResearches have known for more than a decade that the risk of heart disease and stroke increases when people take pain relievers.  Now, scientists from the University of California, Davis have uncovered some of the reasons why these drugs can harm heart tissue.

Click here for more >>

Scleroderma Research Foundation (SRF) Presents Webinar on Improving Function of Hands and Face

The SRF webinar series is designed for patients and others in the scleroderma community to provide a greater understanding of the disease, how to better manage its complications, and share what is being done to find a cure.  On Wednesday, May 11, Dr. Janet Poole, a Professor in the Occupational Therapy Graduate Program at the University of New Mexico will lead a session on improving function of the hands and face.

Video: Improving Your Sexuality

video56.jpg The Federation of European Scleroderma Associations aisbl (FESCA), has released a series of videos that were recorded at the 4th Systemic Sclerosis World Congress earlier this year.  The workshops cover a variety of different topics and features.  This video discusses ways to improve your sexuality and other relationship questions.

Click here to watch the entire video >>

Traveling While Gluten Free - A Survival Guide

Gluten-Free-Grocery-Store-Aisle.jpgAwareness of celiac disease may be on the rise but many places have never heard of it.  Patience is required - both in explaining the issue and handling mistakes.  Thankfully there are far more options available now than ever before.

Click here to read more >>

Clinical Trial Update

Systemic Scerosis Responds to Actemra in Early Trial

Interleukin (IL)-6 inhibition with tocilizumab (Actemra) may offer benefit in the treatment of systemic sclerosis, a phase II proof-of-concept study suggested.  At week 48, the change in mean Rodnan skin score from baseline among patients receiving tocilizumab was -6.33 compared with a change of -2.77 among those given placebo, for a difference of -3.55 (95% CI -7.23 to 0.12, P=0.06), according to Christopher Denton, MD, of University College London.

Click here for more >>

 


 
Quick Links
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Home
facebook_32.png
twitter_32.png
Youtube_32x32.png

Actelion 2016 sponsor
2016 Bayer Logo
2016 Bronze National Sponsor Reata
2016 Gilead Silver Conference Sponsor
Genentech
United Therapeutics Logo
 

 

 

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2017 All rights reserved.